Abstract: Two biomarkers are provided for obstructive apnea. A first biomarker determines amplitude and timing of inspiratory efforts from a bioelectric signal. The respiratory rate is compared with a normal pre-detection rate, and the amplitude of the effort is compared with a normal amplitude. The obstructive apnea is likely present if a series of inspiratory efforts are above a normal amplitude and with increasing amplitude, but at a normal rate. A second biomarker determines heart rate and respiratory rate. A normal lower threshold for heartbeat interval is established, and if subthreshold events occur (short RR intervals), a commencement time for each sequence of subthreshold events is compared for a respiratory rate-normalized window. If the number of subthreshold events exceeds a minimum for the window, obstructive apnea is likely present.

Abstract: The invention is a multi-firepot pellet grill that provides zoned cooking. The design incorporates two or more heat sources, strategically positioned within the cooking chamber, to provide consistent and even heat distribution, enabling a wider variety of cooking techniques, including zone cooking. In one or more embodiments, the invention incorporates a PID (Proportional-Integral-Derivative) controller with or without altitude compensation technology to maintain precise temperature control.

Abstract: In accordance with a designation of a private alias endpoint as a routing target for traffic directed to a service from within an isolated virtual network of a provider network, a tunneling intermediary receives a baseline packet generated at a compute instance. The baseline packet indicates a public IP (Internet Protocol) address of the service as the destination, and a private IP address of the compute instance as the source. In accordance with a tunneling protocol, the tunneling intermediary generates an encapsulation packet comprising at least a portion of the baseline packet and a header indicating the isolated virtual network. The encapsulation packet is transmitted to a node of the service.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

Abstract: A coated barrier fabric for use in a reusable medical product (e.g., surgical gown, surgical drape, etc.) is provided and has two woven or knitted plies. Each of the two plies are coated on one side with a non-fluorine containing polymer and retain similar comfort and feel of uncoated woven or knitted fabrics. The coated sides of the plies face each other (i.e., inwardly) in the interior of the barrier fabric. Because of the orientation of the plies, the coated sides of the plies can come into direct contact with and move freely against each other within the interior of the barrier fabric. The coating on each of the plies is protected from exterior and environmental factors, including repeated institutional laundering/autoclave cycles, that could abrade and degrade the coating. Thus, the useful life of the reusable medical product including the barrier fabric is extended.

Abstract: A personal protective equipment (PPE) rear opening isolation gown is provided that can be used by workers in the healthcare industry. The isolation gown is reusable and can provide for ease of doffing, such as in a pull forward manner that is consistent with how current users of disposable isolation gowns are accustomed to removing such gowns, without substantial risk of damaging (e.g., tearing) the gown and without substantial risk of the transfer of potentially harmful microorganisms, body fluids, and/or particulate material, to the neck or hair on the head or neck of a wearer. The reusable, rear opening isolation gown is provided with an easy release fastener(s) that provides a safe and secure hold when fastened but permits the gown to be removed easily, quickly, and more safely than other reusable options.

Abstract: This present patent application discloses a card cover. The card cover comprises of a front and a back panel including various gray-out and transparent portions. The card cover provides users with a privacy cover for identification cards, debit and credit cards, and more, and maintains privacy for the user, preventing personal information from being revealed to unauthorized individuals when using the card. The device features several ‘gray-out’ portions on the cover to protect information on the card and ensures bystanders, retail employees, and the like are unable to view specific information, preventing identity theft and other dangers involving personal information. The transparent portion shows the non-confidential information present on the card for easy access of the card.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: The invention provides compounds of formula (I) wherein R is —CH3 or —CH2CH3 and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKKE, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them.

Abstract: An adjustable height bed skirt is provided for covering a gap defined between a mattress of a bed and a floor surface upon which the bed sits. The bed skirt includes a decking panel with a plurality of fastening strips spaced-apart from one another and extending along the bottom edge and side edges of the decking panel. A skirt panel includes a fastening strip that can be removably coupled to one of the plurality of fastening strips on the decking panel to adjust a vertical drop height that the skirt panel covers as it extends along three sides of the bed. The skirt panel includes corner pleats and the decking panel includes bottom corner portions, each of which do not include the fastening strips. Additionally, color-coded indicia elements are applied to the fastening strips on the decking panel to assist with connecting the skirt panel in the desired position.

Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Abstract: This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.